SCHEMBL2803946

SCHEMBL2803946

O=S(=O)(NC1CCc2c(cnc3[nH]ncc23)C1)c1ccc(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.50
PIK3CA P42336 2/20 0.40
RB1 P06400 1/20 0.38
DPP4 P27487 6/20 0.38
DPP7 Q9UHL4 5/20 0.38
KCNH2 Q12809 4/20 0.38
SGK1 O00141 2/20 0.37
PAK1 Q13153 2/20 0.37
POLB P06746 1/20 0.36
BRD4 O60885 1/20 0.36
DPP8 Q6V1X1 2/20 0.36
DPP9 Q86TI2 2/20 0.36
MAP2K7 O14733 1/20 0.35
MAP2K4 P45985 1/20 0.35
AHR P35869 1/20 0.34
NTRK1 P04629 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803256 0.90 HDAC8 (0.42) HDAC8PIK3CARB1SGK1PAK1
SCHEMBL2806649 0.90 HDAC8 (0.40) HDAC8RB1SGK1BRD4MAP2K7
SCHEMBL2806698 0.90 HDAC8 (0.40) HDAC8PIK3CARB1SGK1PAK1
SCHEMBL2805612 0.90 HDAC8 (0.40) HDAC8SGK1
SCHEMBL2805651 0.90 HDAC8 (0.42) HDAC8PIK3CARB1SGK1PAK1
SCHEMBL2802832 0.89 USP30 (0.43) HDAC8RB1SGK1BRD4MAP2K7
SCHEMBL2804182 0.88 SGK1 (0.43) HDAC8RB1SGK1
SCHEMBL2805699 0.86 RB1 (0.52) HDAC8RB1PAK1MAP2K7MAP2K4
SCHEMBL2805284 0.85 SGK1 (0.46) SGK1
SCHEMBL2802245 0.85 SCN1A (0.35) HDAC8RB1SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HDAC8 615/4885PIK3CA 188/4885RB1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.